- January 24, 2023 08:42 AM CET
- January 18, 2023 08:30 AM CET
Oryzon Genomics Informs On Conversion Of Convertible Bonds
- January 17, 2023 08:46 AM CET | Reuters
Jan 17 (Reuters) - Oryzon Genomics SA: * ANNOUNCES CONVERSION OF CONVERTIBLE BONDS * INVESTOR NICE & GREEN HAS REQUESTED A NEW CONVERSION OF BONDS FOR AN AMOUNT JOINT FACE VALUE OF 1.9 MILLION EUROS,Read More...
Grifols Achieves Positive Topline Results From Phase 3B Study Of Fibrin Sealant
- January 11, 2023 02:07 PM CET | Reuters
Jan 11 (Reuters) - Grifols SA: * ACHIEVES POSITIVE TOPLINE RESULTS FROM PHASE 3B STUDY OF ITS FIBRIN SEALANT TO TREAT SURGICAL BLEEDING IN PEDIATRIC PATIENTS * ALL PRIMARY AND SECONDARY ENDPOINTS MET,Read More...
Pharma Mar Initiates First Human Clinical Trial Of New Molecule For Cancer Patients
- December 30, 2022 08:33 AM CET | Reuters
Dec 30 (Reuters) - Pharma Mar SA: * INITIATES FIRST HUMAN CLINICAL TRIAL OF A NEW MOLECULE, PM534, FOR CANCER PATIENTS * NEW MOLECULE HAS BEEN TESTED IN THE LABORATORY, BOTH IN CELL CULTURES (IN VITRORead More...
Pharma Mar Leads Research Project In Search Of Immunotherapies Based On Marine-Derived Compounds
- December 22, 2022 08:54 AM CET | Reuters
Dec 22 (Reuters) - Pharma Mar SA: * LEADS TERINMUN INITIATIVE, RESEARCH CONSORTIUM IN SEARCH OF IMMUNOTHERAPIES BASED ON MARINE-DERIVED COMPOUNDS * PROJECT APPROVED IN CALL FOR PUBLIC-PRIVATERead More...
Oryzon Genomics: Investor Nice & Green Converts Bonds For Nominal Amount Of 1.8 Mln Euros
- December 20, 2022 04:50 PM CET | Reuters
Dec 20 (Reuters) - Oryzon Genomics SA: * CONVERSION OF CONVERTIBLE BONDS * INVESTOR HAS PROCEEDED TO CONVERT BONDS FOR A NOMINAL AMOUNT SET OF 1.8 MILLION EUROS, AT A CONVERSION PRICE OF 2.1995 EUROSRead More...
Oryzon Genomics Gets EU Grant To Explore Iadademstat Role In Oncological Immunotherapy Approaches
- December 16, 2022 08:00 AM CET | Reuters
Dec 16 (Reuters) - Oryzon Genomics SA: * GETS EU GRANT TO FURTHER EXPLORE ROLE OF IADADEMSTAT IN ONCOLOGICAL IMMUNOTHERAPY APPROACHES * PROJECT WILL START ON MAY 1, 2023 AND WILL RUN FOR TWO YEARS *Read More...
Grifols considers selling 2 bln euros worth of assets to cut debt, Cinco Dias says
- December 14, 2022 10:00 AM CET | Reuters
MADRID, Dec 14 (Reuters) - Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citingRead More...
Laboratorio Reig Jofre Completes Co-Development Of Trifertyatm
- December 13, 2022 11:49 AM CET | Reuters
Dec 13 (Reuters) - Laboratorio Reig Jofre SA: * HAS SUCCESSFULLY COMPLETED CO-DEVELOPMENT OF TRIFERTYATM, FOOD SUPPLEMENT THAT CONTRIBUTES TO MALE FERTILITY Further company coverage: (Gdansk Newsroom)Read More...
Frequently Asked Questions